Myristoleic acid( (Z)-Tetradec-9-enoic acid | cis-9-tetradecenoic acid | 9-Tetradecenoic acid )

Catalog No. M28356 CAS No. 544-64-9

Myristoleic acid is a cytotoxic component in the extract from Serenoa repens. Myristoleic acid induces apoptosis and necrosis in human prostatic LNCaP cells.

Purity : >98% (HPLC)

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Size	Price / USD	Stock	Quantity
5MG	26	In Stock
100MG	Get Quote	In Stock
200MG	Get Quote	In Stock
500MG	Get Quote	In Stock
1G	Get Quote	In Stock

Get Quotation Bulk Inquiry Add to Cart

Biological Information

Product Name

Myristoleic acid
Note

Research use only, not for human use.
Brief Description

Myristoleic acid is a cytotoxic component in the extract from Serenoa repens. Myristoleic acid induces apoptosis and necrosis in human prostatic LNCaP cells.
Description

Myristoleic acid is a cytotoxic component in the extract from Serenoa repens. Myristoleic acid induces apoptosis and necrosis in human prostatic LNCaP cells.(In Vitro):Myristoleic acid induces both necrosis (100 μg/mL, 81.8%) and apoptosis (100 μg/mL, 89.5%) in LNCaP cells . Myristoleic acid inhibited RANKL-induced osteoclast formation in vitro, especially, at later stages of differentiation. (In Vivo):Myristoleic acid (2 mg/kg, IP every 24 h for 4 days) prevents RANKL-induced bone loss and osteoclast formation in mice .
In Vitro

Myristoleic acid induces both apoptosis (100 μg/mL, 89.5%) and necrosis (100 μg/mL, 81.8%) in LNCaP cells. Myristoleic acid inhibited RANKL-induced osteoclast formation in vitro, especially, at later stages of differentiation. Cell Proliferation Assay Cell Line:Human prostatic carcinoma LNCaP cells.Concentration:0, 50, 100, 150, 200, 250 μg/mL.Incubation Time:24 h.Result:When LNCaP cells were treated with 130 μg/mL extract or 100 μg/mL myristoleic acid for 24 hr, the proportion of apoptotic cells was 16.5 and 8.8%, and that of necrotic one was 46.8 and 81.8%, respectively.
In Vivo

Myristoleic acid (2 mg/kg, IP every 24 h for 4 days) prevents RANKL-induced bone loss and osteoclast formation in mice. Animal Model:C57BL/6 mice at 5 weeks. Dosage:0.2, 2 mg/kg Administration:IP every 24 h for 4 days.Result:Co-administration of myristoleic acid suppressed generation of TRAP-positive osteoclasts induced by sRANKL and attenuated the increases in osteoclastic indices of Oc.S/BS, N.Oc/B. Pm and ES/BS in a dose-dependent manner.
Synonyms

(Z)-Tetradec-9-enoic acid | cis-9-tetradecenoic acid | 9-Tetradecenoic acid
Pathway

Apoptosis
Target

Apoptosis
Recptor

SARS-CoV-2
Research Area

——
Indication

——

Chemical Information

CAS Number

544-64-9
Formula Weight

226.36
Molecular Formula

C14H26O2
Purity

>98% (HPLC)
Solubility

In Vitro:?DMSO : ≥ 100 mg/mL (441.77 mM)
SMILES

CCCC\C=C/CCCCCCCC(O)=O
Chemical Name

——

Shipping & Storage Information

Storage

(-20℃)
Shipping

With Ice Pack
Stability

≥ 2 years

Reference

1.Han SH, et al. Structure-Based Optimization of ML300-Derived, Noncovalent Inhibitors Targeting the Severe Acute Respiratory Syndrome Coronavirus 3CL Protease (SARS-CoV-2 3CLpro). J Med Chem. 2022 Feb 24;65(4):2880-2904.

Calculator

Molecular Weight Calculator

Dilution Calculator

Molarity Calculator

molnova catalog

Product			Quantity Required*
Name *			E-mail Address *
Organization *			Phone Number
Remarks